Previous studies have demonstrated that activation of calcineurin induces pathological cardiac hypertrophy (CH). In these studies, loss-of-function was mostly achieved by systemic administration of the calcineurin inhibitor cyclosporin A. The lack of conditional knockout models for calcineurin function has impeded progress toward defining the role of this protein during the onset and the development of CH in adults. Here, we exploited a mouse model of CH based on the infusion of a hypertensive dose of angiotensin II (AngII) to model the role of calcineurin in CH in adulthood. AngII-induced CH in adult mice was reduced by treatment with cyclosporin A, without affecting the associated increase in blood pressure, and also by induction of calcineurin deletion in adult mouse cardiomyocytes, indicating that cardiomyocyte calcineurin is required for AngII-induced CH. Surprisingly, cardiac-specific deletion of calcineurin, but not treatment of mice with cyclosporin A, significantly reduced AngII-induced cardiac fibrosis and apoptosis. Analysis of profibrotic genes revealed that AngII-induced expression of Tgfb family members and Lox was not inhibited by cyclosporin A but was markedly reduced by cardiac-specific calcineurin deletion. These results show that AngII induces a direct, calcineurin-dependent prohypertrophic effect in cardiomyocytes, as well as a systemic hypertensive effect that is independent of calcineurin activity.
Introduction
Cardiac hypertrophy (CH) is the main mechanism by which the heart reduces stress on the ventricular walls [1] [2] [3] . In the initial response to cardiac overload, heart function is maintained through increased protein synthesis and cardiomyocyte enlargement, accompanied by sarcomere reorganization. This cardiac response can be induced in physiological or pathological situations. During pregnancy or intensive exercise training, CH is an advantageous adaptation; however, in response to hypertension, aortic stenosis, or myocardial infarction, the initial compensatory response to cardiac stress becomes maladaptive and constitutes a major risk for the development of heart failure [4] .
The precise mechanisms underlying physiological and pathological CH are not fully understood; however, pathological cardiac remodeling is characterized by the development of fibrosis that contributes to loss of heart function. Several studies indicate that physiological and pathological cardiac remodeling involve different biochemical stimuli and intracellular signaling pathways, which could explain their differing outcomes [1] [2] [3] . Physiological CH is triggered by a limited number of growth factors (thyroid hormone, insulin, insulin-like growth factor 1, and vascular endothelial growth factor) and mechanical stimuli that activate the IGF1/PI3K/AKT-, ERK1/2-, AMPK-, and mTOR-dependent signaling pathways. In contrast, pathological hypertrophy is activated by a plethora of neuro-hormonal factors and biomechanical stimuli and intracellular pathways, including MAPK kinases, GRK-, PDE5-, PKCa-, CAMKII-, and Ca 2+ -dependent effectors. Prominent inducers of pathological CH include the calcium-calmodulindependent phosphatase calcineurin (Cn) and its substrate NFAT [5] . Although numerous gain-offunction studies have demonstrated that Cn and NFAT both induce a pathological phenotype involving cardiac growth [5, 6] , most loss-of-function experiments have been performed with the pharmacological Cn inhibitors cyclosporin A (CsA) and FK506 (tacrolimus) or mice constitutively lacking Cn or NFAT [5] . To date, two studies have described the generation of mice with cardiac-specific loss of Cn in the heart, by deletion of the Cnb1 gene [7, 8] . However, the use of a noninducible cardiomyocyte driver in these mice causes cardiac Cn deletion in the perinatal period, when cardiomyocytes are proliferating [9] , resulting in depressed cardiac function and 50% lethality at 4-6 months [7, 8] . To our knowledge, no mouse model to date has modeled the role of cardiac Cn during CH in adulthood, when the disease develops.
Hypertension is a major inducer of pathological cardiac remodeling characterized by left ventricular hypertrophy and cardiac fibrosis [4, 10] . High blood pressure, such as that induced by angiotensin II (AngII), is a well-known mediator of CH [11] . Recent evidence suggests that AngII also exerts a pressorindependent and direct action on cardiac remodeling [12] [13] [14] . Previous studies in animal models of hypertension demonstrated the participation of Cn in CH [15] [16] [17] ; however, the precise role of Cn in CH onset and progression has not been defined. For the present study, we generated a mouse model of inducible and cardiac-specific Cn deletion. Through a combination of genetic experimental and pharmacological approaches, we show that Cn plays an essential role in the development of AngII-mediated CH, whereas cardiac fibrosis is mediated by CsA-insensitive mechanisms involving members of the Tgfb and Lox families.
Results
A Cn-inhibitory CsA concentration reduces AngIIinduced cardiac hypertrophy in mice without affecting hypertension
CsA at higher doses than those used therapeutically to achieve Cn inhibition and immunosuppression [18, 19] ). Levels of a-Actinin (a-Act) were determined as a loading control. (D-F) Analysis of CH in mice treated as indicated for 1 or 3 days. (D) Ratios of ventricular weight to body weight (VW/BW) and ventricular weight to tibia length (VW/TL). (E) Cardiomyocyte cross-sectional area. (F) Interventricular septum wall thickness. Histograms show individual data and means AE SEM (n = 12-14 mice per group, three independent experiments in D and n = 9-12 mice per group, two independent experiments in E and F). All data were analyzed by one-way ANOVA with a post hoc Tukey's comparison test, the adjusted P values are shown. *P: Parameters in D were compared by unpaired, two-tailed Student's t-test.
reduces CH induced by nonpressor doses of AngII in rats [20] . We therefore tested whether lower (clinical) doses of CsA would prevent CH induced by prohypertensive AngII concentrations. We treated wild-type mice for 21 days with AngII (60 lgÁkg À1 Áh
À1
) and a pharmacological CsA dose (0.208 mgÁkg À1 Áh À1 ). This
CsA dose is 10-fold below that used in rats [20] . AngII induced an increase in systolic blood pressure (Fig. 1A) .
To determine whether the AngII-induced increase in cardiac mass was due to increased cardiomyocyte size, we measured cardiomyocyte cell area in cardiac cross sections. Cardiomyocyte area was significantly enlarged in AngII-infused mice, and this increase was again attenuated by CsA (Fig. 1B) . Consistent with these morphological data, echocardiography in live AngII-infused mice revealed notable increases in left ventricular posterior wall (LVPW) and interventricular septum (IVS) thickness (Table 1) . CsA did not modify ventricular wall thickness in sham-implanted animals, but attenuated the increase in wall thickness induced by AngII infusion ( Table 1) . Analysis of ejection fraction (EF) revealed that AngII and CsA treatment had no significant impact on systolic cardiac function (Table 1) .
These results suggest that Cn activation plays an important role in AngII-induced CH and indicate that pharmacological Cn inhibition with CsA significantly reduces cardiac enlargement without reverting AngIIinduced hypertension.
AngII triggers early activation of Cn-dependent gene expression and the cardiac hypertrophy program
We next investigated whether AngII activates Cndependent gene expression in the heart. Cardiac mRNA expression of the Cn target genes Rcan1. 4 and Ptgs2 [21, 22] was elevated in wild-type mice after AngII treatment for 15 h, decreasing to basal levels after 3 days ( Fig. 2A) . This transcriptional effect was reflected in the induction of cardiac Rcan1.4 and Cox-2 protein expression as soon as 1 day after treatment (Fig. 2B,C) . Rcan1.4 expression returned to baseline levels after 2 days of AngII infusion, whereas maximum Cox-2 expression was maintained at this time (Fig. 2C) (Fig. 2B,C) , suggesting that Cn activation was required for their upregulation.
Given that AngII induced a very early activation of cardiac Cn-dependent gene expression, we analyzed whether AngII treatment also results in an early development of the hypertrophic phenotype. CH development was monitored in wild-type mice treated with AngII for 1 or 3 days. Notably, as early as 3 days after the initiation of AngII infusion, mice showed significant increases in ventricular mass (Fig. 2D) , cardiomyocyte area (Fig. 2E) , and IVS thickness (Fig. 2F ). This early AngII-induced CH was attenuated by treatment with CsA ( Fig. 2D-F) .
These results show that AngII induces an early expression of Cn-dependent genes in the heart that is concomitant with the early appearance of a CH phenotype. The blockade of these effects with Cn inhibitors suggests that activation of Cn signaling mediates AngII-induced CH.
AngII-induced CH requires cardiomyocyte Cn
Although our experiments were performed with low CsA concentration, this immunosuppressant can have effects unrelated to Cn and might interfere with targets others than Cn [23] . Knockout models in principle represent a more precise alternative to the use of pharmacological Cn inhibitors. However, none of the reported mouse models allows the study of the role of Cn in the development of CH, a condition of adulthood: mice systemically lacking Cnb1 die during embryogenesis [24] , and Cn deletion using the alphamyosin heavy chain (Myh6) promoter results in death in early-mid-adulthood [7, 8] . To address this issue, we generated a mouse model allowing induced cardiomyocyte-specific deletion of floxed Cnb1. In these mice, Cnb1 deletion is induced in cardiomyocytes expressing Cre recombinase under the control of the Myh6 promoter in a tamoxifen-inducible manner. Cnb1 Δ/flox mice [25] were crossed with Myh6
CreERT2 mice [26] Fig. 3A ). Western blot analysis revealed unaltered CnB protein expression in thymus, aorta, liver, and kidney of Tx-treated Cnb1-flox Myh6 mice (Fig. 3B ), confirming specific deletion in cardiac tissue. The destabilization of the catalytic subunit CnA in the absence of the regulatory subunit CnB has been previously demonstrated in in vivo models [7, 27] . Similarly, we confirmed that the deletion of cardiac Cnb1 expression resulted in a similar reduction in the protein levels of both CnB and CnA ( Fig. 3A and Fig. S1B ).
Having confirmed the specificity and efficacy of Cn deletion in Tx-treated Cnb1-flox Myh6 mice, we infused them with AngII for 1 day and determined the cardiac mRNA expression of the Cn target genes Rcan1.4 and Ptgs2, as an index of Cn pathway activity. Rcan1.4
and Ptgs2 mRNA levels were markedly lower in Tx-treated mice than in untreated controls (Fig. 3C) , and similar results were obtained for Rcan1.4 protein (Fig. 3D) , suggesting that inducible, cardiac-specific Cn ablation inhibits the expression of Cn-dependent genes in the hearts of AngII-treated mice.
We next analyzed the effect of cardiac Cnb1 deletion in adult mice on AngII-induced CH. Mice treated with Tx or vehicle were infused with AngII for 21 days. The induced loss of cardiac Cn diminished AngII-induced increases in ventricular mass and cardiomyocyte cross-sectional area (Fig. 4A,B) , and echocardiography confirmed attenuation of the AngIIinduced increase in left ventricular wall thickness (Table 2 ). Induced cardiac Cnb1 deletion was equally effective as CsA-mediated inhibition of Cn phosphatase activity at preventing AngII-induced CH. These results implicate cardiomyocyte Cn in CH and validate Cnb1-flox Myh6 mice as a model for investigating the mechanisms underlying the onset and progression of hypertrophy in the adult heart.
Cardiac Cn mediates AngII-induced fibrosis and profibrotic gene expression
Cardiac fibrosis -the abnormal accumulation of extracellular matrix proteins (ECM) such as collagens and fibronectins in the myocardium -is a common feature of pathological CH [2] . In wild-type mice, AngII treatment for 21 days induced significant myocardial fibrosis that was not prevented by CsA (Fig. 5A) . Histological analysis at earlier time points revealed marked cardiac fibrosis on day 3 of AngII stimulation; CsA not only did not prevent this but seemed to exacerbate it (Fig. 5B) . The histological data correlated with the mRNA expression of Col3a1, which encodes one of the two fibrillar collagen types that form the myocardial extracellular matrix (Fig. 5C ). These results suggest that AngII-induced cardiac fibrosis is Cn-independent; however, AngII-mediated cardiac fibrosis was strongly reduced by Cn deletion in the cardiomyocytes of Cnb1-flox Myh6 mice (Fig. 5D ). As in wild-type mice, CsA did not prevent AngII-induced heart fibrosis in Cnb1-flox Myh6 mice, demonstrating that the divergence between the results obtained with pharmacological and genetic Cn inhibition was not due to the use of different mouse strains (Fig. 5D ). As observed in mice treated with AngII for 21 days, the cardiac Cnb1 deletion attenuated CH and fibrosis as early as 3 days after AngII infusion (Fig. 6) .
Cardiomyocyte death has been described as a possible mechanism responsible for induction of the fibrotic response [28] , and the presence of apoptotic cells in cardiac tissue has been widely reported in AngII-treated rodents [11, 29, 30] . TUNEL assays to evaluate the extent of apoptosis in AngII-treated mice in the pharmacological and genetic models revealed a significant increase in the number of apoptotic cells after 3 days of AngII treatment (Fig. 7A,B) . Similar to the fibrotic response, AngII-induced heart apoptosis was unaffected by CsA and was prevented by Cn deletion in cardiomyocytes (Fig. 7A,B) . Apoptosis and fibrosis thus show the same divergence in the response to pharmacological and genetic Cn inhibition.
The elevated and abnormal deposition of collagens during cardiac fibrosis is regulated at the levels of synthesis, maturation, and degradation [31] . Cytokines and growth factors implicated in fibrosis induction include interleukin-6 (Il-6) and members of the Tgfb family [32] . We therefore examined whether the expression of profibrotic genes was differently affected by pharmacological and genetic Cn inhibition during AngII-induced cardiac fibrosis. Gene expression of Il6, Tgfb1, Tgfb2, and the Tgfb-induced gene Tgfbi was significantly upregulated in the hearts of wild-type mice after 1 day of AngII infusion, whereas Tgfb3 mRNA was significantly increased after AngII infusion for 3 days (Fig. 8A) . Analysis of gene expression in the hearts of Tx-treated Cnb1-flox Myh6 mice and CsA-treated wildtype mice revealed suppression of AngII-induced Il6 expression in both cases, whereas AngII-induced Tgfb3 upregulation was unaffected (Fig. 8B) . In contrast, AngII-induced Tgfb1, Tgfb2, and Tgfbi expression was not inhibited by CsA in wild-type mice but was reduced by cardiac-specific Cnb1 deletion (Fig. 8B) . Tgfb family members can trigger the activation and maturation of collagen expression [32] , suggesting that the differential Tgfb expression pattern might underlie the divergent fibrotic phenotypes observed. However, AngII-induced mRNA expression of Col1a1 and Col3a1 was not reduced in response to cardiac Cnb1 deletion, and CsA further potentiated their expression (Fig. 8C) .
Processing of collagens into mature fibrils requires covalent cross-linking mediated by members of the lysyl oxidase family [33] , the most prominent member is Lox. AngII-induced upregulation of Lox mRNA expression was not affected by CsA treatment in wildtype mice, but was significantly decreased by deletion of cardiomyocyte Cn (Fig. 8D ). This pattern was reflected at the protein level, with AngII-induced Lox protein expression not reduced by CsA, and even increased, whereas cardiac Cnb1 deletion blunted this upregulation (Fig. 8E) . As reported for transaortic constriction-induced CH [34] , AngII also upregulated the other Lox family members (Loxl1, Loxl2, Loxl3, and Loxl4) in the heart (Fig. 9) . Cardiac Cnb1 deletion blocked AngII-induced upregulation of Loxl4, but not Loxl1, Loxl2, or Loxl3 (Fig. 9 ).
These results indicate that cardiomyocyte Cn regulates AngII-induced cardiac fibrosis and expression of essential profibrotic genes in murine heart. (right) after AngII infusion for the optimal period for each gene, obtained from results in A (1 day after AngII infusion except for Tgfb3, which was analyzed 3 days after AngII infusion). Data are mean AE SEM (n = 4-6 mice per group for Il6 and Tgfb3; n = 7-14 mice per group for Tgfb1, Tgfb2, and Tgfbi). mice per group). Data in B-D were obtained from three independent experiments, and were analyzed by one-way ANOVA with a post hoc Tukey's comparison test, *P value was acquired by unpaired, two-tailed Student's t-test. (E) Western blot analysis of Lox protein expression in cardiac protein lysates isolated from the experimental mouse models described above after AngII infusion for 3 days. Levels of a-Tub were determined as a loading control; n = 3-5 mice per group. Arrows indicate the specific Lox protein band.
Discussion
In this study, we provide evidence demonstrating that AngII at hypertensive doses activates Cn signaling in the mouse heart concurrently with the development of CH. Remarkably, inhibition of Cn with low CsA doses impaired AngII-induced CH but did not reverse the associated blood pressure increase, suggesting that AngII exerts a direct Cn-dependent prohypertrophic effect on cardiac cells and an indirect Cn-independent hypertensive effect. These results are consistent with CsA-mediated reduction of AngII-linked CH in other mouse models, including renal damage-induced CH [16] and aldosterone-induced CH [17] . Our findings indicate that in a pathological setting AngII directly activates specific prohypertrophic pathways in cardiac cells that differ from those triggered by hypertension-derived hemodynamic stimuli. Supporting this idea, subpressor AngII doses induce CH in rats [20] . Furthermore, AngII-dependent activation of p38 MAPK signaling has been linked to a direct action on mouse cardiac cells, whereas activation of Erk and Jnk is linked to AngII-induced mechanical stress on the heart [35] . These results suggest that treatment of pathological CH in patients presenting high blood pressure would require blockade of specific intracellular pathways activated by hypertension-independent mechanisms. Pharmacological inhibition of Cn with CsA is a useful tool for investigating the involvement of Cn in CH progression. However, systemic drug delivery does not target the specific contribution of cardiac Cn. Here, we explored the precise implication of cardiac Cn in the onset and progression of CH in adulthood, using a newly generated mouse model of inducible cardiomyocyte-specific Cnb1 deletion, based on floxed Cnb1 and Cre recombinase expression under the control of the inducible cardiac promoter Myh6. In this mouse model, deletion of CnA and CnB occurs in a similar manner, which implies that Cn-mediated phosphatase activity in the heart is inhibited upon conditional deletion of Cnb1, as this also led to the loss of the Cn catalytic subunit (CnA). These results therefore suggest that genetic and pharmacological approaches both result in the inhibition of Cn activity.
We have found that conditional deletion of cardiomyocyte Cnb1 prevents AngII-induced CH. These results are consistent with previous reports showing inhibition of AngII-mediated heart weight gain in mouse models with constitutive deficiency of the catalytic subunit CnAb or the Cn substrates NFATc3 or NFATc2 [36] [37] [38] . However, it is important to note that these studies examined induction of CH by pressure overload or Cn overexpression, which are not mediated by systemic hypertension, and AngII was used only to confirm that deletion of these Cn/NFAT signaling pathway components were involved in AngII-mediated heart weight increase. Here, we have characterized the CH induced by a well-characterized prohypertensive dose of AngII [39] [40] [41] [42] and analyzed the role of cardiomyocyte Cn in cardiomyocyte size, ventricular wall thickness, fibrosis, expression of profibrotic genes, and apoptosis. Our data indicate that cardiomyocyte Cn in adulthood regulates cardiac remodeling and function during the onset and development of AngII-mediated CH.
Remarkably, cardiac-specific Cn deletion in healthy adult mice did not impair cardiac function (Tx-treated sham-implanted Cnb1-flox Myh6 mice, Table 2 ). A cardiac-specific Cn knockout mouse was recently generated [7, 8] , but in this model, cardiac Cn deletion is not inducible and begins at the perinatal stage, resulting in impaired contractility and cardiac growth, and death between 4 and 6 months after birth [7, 8] . The differences between these results and ours suggest that Cn plays different roles in cardiac homeostasis during postnatal development and adulthood and are consistent with data showing that Cn signaling differs between neonatal and adult cardiomyocytes [43] .
Although most animal models of CH are based on chronic stimulation, we show here that mice display Cn-dependent CH markers as soon as 3 days after AngII infusion (Figs 2 and 6 ). Our results show that AngII-induced activation of cardiac Cn mediates CH progression from the onset of the disease. We also found that Cn inhibition by CsA infusion or cardiacspecific Cnb1 deletion prevents AngII-induced cardiomyocyte hypertrophy. However, these two approaches to Cn inhibition have divergent effects on AngII-induced cardiac fibrosis, which was unaffected by CsA but impaired by cardiac-specific Cnb1 deletion. In fact, our results in fibrosis using genetic approach are consistent with those obtained by overexpressing specifically in the heart the Cn inhibitor, RCAN1 [44] .
The effect of CsA treatment on different CH models has been broadly studied, obtaining controversial results about its CH inhibitory capacity [45] . Most studies that describe a CsA inhibitory effect on CH does not focus on its effect on fibrotic process induced in CH, and few studies that analyze it show opposing results. CsA-mediated fibrosis attenuation [15] and exacerbation [46] have been described in AngII-nonlinked CH, while there is only one study in which it is described that CsA inhibits cardiac fibrosis mediated by an AngII-linked model, uninephrectomized and aldosterone-treated rats [17] . However, the result of systemic pharmacological inhibition of Cn on AngIIinduced cardiac fibrosis has not been analyzed until the present work. The different doses of CsA and/or different hypertrophic stimuli used in these studies could explain the discrepancies found.
Several studies have described myocardial fibrosis as a potential CsA side effect [46, 47] , providing a possible explanation for the fibrotic phenotype in CsA-treated animals. However, this is unlikely to be the case in our experiments because CsA did not increase myocardial fibrosis in sham-implanted, wild-type animals. In previous studies showing CsA-promoted fibrosis [46] [47] [48] , the experiments used much higher CsA concentrations than those used here, suggesting that the profibrotic effects might represent off-target effects on molecules other than Cn [23, 49] . Cardiac fibrosis induction can be in part a response to cell death [28] , and high doses of CsA induces apoptosis [50] . In our genetic and pharmacological models, we found that the apoptotic and fibrotic responses follow a similar pattern in both experimental settings, and that CsA per se does not induce apoptosis. CsA has also been found to increase Tgf-b1 levels in biopsies from immunosuppressed patients, animal models, and cells exposed to the drug in vitro [51] [52] [53] . A mechanism proposed for this effect is CsA-enhanced Tgf-b1 synthesis. However, in mice treated with CsA alone we detected no increase in cardiac Tgfb1 mRNA (data not shown). Although we observed no CsA-mediated effect that explains the fibrosis results in CsA/AngII-treated mice, we cannot exclude the possibility that CsA post-transcriptionally or post-translationally modifies a factor or factors involved in fibrosis [54, 55] , producing an effect that is insufficient to induce fibrosis on its own but sufficient to maintain the induction of Tgfb/fibrosis mediated by AngII.
An alternative hypothesis consistent with our results is that, in addition to its well-known phosphatase action, cardiac Cn is essential for the assembly of molecular signaling complexes in specific cardiomyocyte subdomains that could be implicated in AngII-induced fibrosis. Supporting this idea, anchoring of Cn to the sarcomere Zdisk is critical for the integration of cardiomyocyte stress signals [43] . Other possible explanations for divergent effects on AngII-induced cardiac fibrosis in two approaches to Cn inhibition may lie in the intricate intercellular cross talk between fibroblasts and cardiomyocytes that have been described during AngII-cardiac remodeling [56] . In contrast to cardiomyocyte-specific Cnb1 deletion, systemic inhibition of Cn mediated by CsA could have adverse profibrotic effect in other cell types of the heart or reveal differences in the Cn susceptibility to its activity inhibition by CsA depending on the cellular context in the similar way that differences in susceptibility of each tissue has been described [57] . Advances in the generation of Cre recombinase gene-targeted mice are enabling specific genetic manipulation of fibroblasts or differentiated myofibroblasts [58] . Future experiments taking advantage of these advances will allow us to explore the contribution of this cardiac cellular compartment to the observed fibrotic effects and to analyze possible differences in Cn susceptibility to drug-mediated inhibition depending on each cellular compartment.
In recent years, new factors have been identified and characterized that trigger and maintain the myocardial fibrotic response in different cardiac diseases [59] . An important role in pathological cardiac fibrosis was recently described for the lysyl oxidase (Lox) family of enzymes, which catalyze collagen assembly [34, [60] [61] [62] [63] . Here, we show that suppression of cardiac Cn impairs the transcriptional expression of Lox, which is involved in the progression of a pathological fibrotic response in the heart. However, CsA-mediated Cn inactivation does not affect the expression of Lox family genes or the appearance of a fibrotic phenotype in the injured heart. The inhibition of AngII-induced cardiac fibrosis after cardiac-specific Cnb1 deletion likely involves the regulation of numerous genes; however, the marked inhibition of Tgfb family members and Lox gene expression could probably account by itself for the decrease in the fibrotic phenotype. Tgfb has been identified as an important upregulator of Lox enzymes in several cell types and Fig. 9 . AngII-induced expression of Loxl4 is selectively affected by cardiac-specific Cn deletion. qPCR analysis of Loxl genes (Loxl1, Loxl2, Loxl3, and Loxl4) in the hearts of CsA-treated wild-type mice (left) and Tx-treated Cnb1-flox Myh6 mice (right) after AngII infusion for 1 day. Data are mean AE SEM (n = 6-14 mice per group), and were analyzed by one-way ANOVA with a post hoc Tukey's comparison test, the adjusted P values are shown. *P: For Loxl3 expression in wild-type mice, comparisons between two groups were made by unpaired, two-tailed Student's t-test.
tissues [62, [64] [65] [66] . Therefore, the effect of Cn deletion on the cardiac expression of Tgfb members could also underlie the Lox-mediated reduction in collagen fiber maturation. Thus, the observed effects on fibrosis induction could reflect the direct fibroblast response to changes in Tgfb or Lox expression. However, the effect of Cn deletion on the AngII-mediated apoptotic response in our experiments does not exclude the possibility that the inhibition of fibrosis in the absence of cardiomyocyte Cn is due in part to interference in AngIIinduced cell death. This study reports a novel role of cardiomyocyte Cn, showing that Cn regulates profibrotic gene expression and the progression of pathological cardiac fibrosis. Cardiac-specific Cn suppression is a potentially attractive therapeutic strategy. Future experiments will be required to clarify why cardiac fibrosis is inhibited by Cn genetic deletion but not by treatment with CsA, and future research is thus warranted into adeno-associated virus type 9-based clinical interventions for siRNA-mediated suppression of cardiomyocyte Cn expression. Our results highlight the importance of targeting Cn expression in the design of novel clinical interventions to prevent fibrosis in the injured heart, and also suggest that therapeutic strategies by targeting Lox should be explored. . S1 ). Gross phenotype was assessed in animals of both genotypes maintained to the age of 6 months. In the absence of Cre activation-induced Cnb1 deletion, mice with a single floxed Cnb1 allele (Cnb1 D/flox ) and mice with two floxed Cnb1 alleles (Cnb1 flox/flox ) showed no significant differences in survival (Fig. S1C) . As expected Cnb1 mRNA levels in Cnb1 D/flox mice were 50% of those of Cnb1 flox/flox mice (Fig. S1A) , however, similar CnB protein levels were detected in the different tissues analyzed, irrespective of the presence of one or two alleles Cnb1 gene, supporting haplo-sufficiency for the Cnb1 gene (Fig. S1D) ). CsA-containing minipumps were implanted 2 days before AngII minipumps to ensure pharmacological Cn inhibition before AngII administration. Control mice underwent the same surgical procedure but without minipump implantation (sham-implanted mice) [68] .
Material and methods

Animals
Mice were weighed and sacrificed after 1, 3, or 21 days of AngII treatment. Hearts were removed and the atria excised. The ventricles were weighed and dissected, with one part being processed for histology and another snapfrozen in liquid nitrogen for protein and RNA analysis. Liver, aorta, thymus, and kidneys were also collected in liquid nitrogen. Tibias from left posterior limbs were isolated and measured with a digital caliper.
Echocardiography
Mice were lightly anesthetized with 1.5% isoflurane. Echocardiography was performed in the parasternal longaxis view using the Vevo 2100 System (VisualSonics Inc., Toronto, ON, Canada) with a 30 MHz MS-400 transducer in the two-dimensional guided M-mode. Measurements were taken of diastolic interventricular and left ventricular posterior wall thicknesses, diastolic left ventricular diameter, and left ventricular ejection fraction.
Blood pressure
Blood pressure and heart rate measurements were obtained using a noninvasive computerized tail-cuff system (BP-2000; Visitech Systems, Apex, NC, USA). Conscious mice from each group were placed on a warming plate and a cuff with a pneumatic pulse sensor was attached to the tail. Mice underwent training for 5 days, and on subsequent days the 10 first readings were discarded, and the mean of the following 10 measurements was calculated.
Histology
The central portion of the heart was fixed in 10% formalin solution (Sigma-Aldrich; 501128) and then embedded in paraffin. Transverse heart sections (5 lm) were obtained and used for analysis. To measure the cross-sectional area of left ventricular cardiomyocytes, heart sections were stained overnight at 4°C with 100 lgÁmL À1 FITC-conjugated Triticum vulgaris lectin (Sigma-Aldrich; L-4895). On each section, images were obtained from four fields with a Nikon Eclipse TE 2000-U fluorescence microscope (Nikon, Tokyo, Japan) fitted with a 109 objective. Cardiomyocyte area was calculated from these images using IMAGEJ [69] .
To quantify cardiac fibrosis, serial transverse sections from each ventricle were stained with Picrosirius Red solution (Sigma Aldrich; P-6744-1GA/365548-5G) and the fibrotic area in the total section was quantified using IMAGEJ; fibrosis (red-stained area) was calculated as a percentage of the total section area. In each experiment, values were calculated relative to those from sham-implanted mice.
Apoptosis was detected by terminal dUTP nick-end labeling (TUNEL) assay using the ApopTag Ò Red In Situ Apoptosis Detection Kit (S7165; Millipore, Temecula, CA, USA) with some modifications. Briefly, apoptosis was detected by staining with phosphatase alkaline (PA)-conjugated, anti-digoxigenin antibody. Heart sections were prepared for TUNEL assay according to the manufacturer's instructions. Whole stained heart sections were scanned, and the extent of apoptosis was quantified using NDP.VIEW2 software, Hamamatsu Photonics (Hamamatsu, Japan). The number of apoptotic cells (brown/black nuclei) in myocardium was quantified relative to the total transverse section area (mm 2 ).
Western blotting
Total protein from different tissues was extracted by pulverization with the MagNALyser system (Roche Life Science, Indianapolis, IN, USA) in lysis buffer (20 mM Tris-HCl pH 7.5, 1% Triton X-100, 50 mM NaF, 5 mM MgCl 2 , 500 mM NaCl, 10 mM EDTA, and proteases inhibitors: 100 lM benzamidin, 1 lgÁmL À1 leupeptin, 1 lgÁmL À1 pepstatin, 1 lgÁmL À1 aprotinin, 1 lM ditiotreitol, 1 mM PMSF, and 3 mM EGTA). Homogenates were incubated on a rocking platform for 30 min at 4°C and centrifuged for 15 min at 16 000 g at 4°C, and soluble proteins were collected in the supernatants. Cardiac proteins were extracted in hypotonic buffer as previously described [70] . Briefly, pulverized heart was homogenized with a pestle and glass tube in a mortar and pestle in hypotonic lysis buffer (10 mM Hepes pH 7.4, 1.5 mM MgCl 2 , 10 mM KCl, 0.2% NP-40, 1 mM spermidine, 150 lM spermine, 10 mM MoO 4 Na 2 , and the protease inhibitors listed above). Homogenates were centrifuged for 15 min at 400 g at 4°C, and cytosolic proteins were collected in the supernatants. For both extractions, protein was quantified with the Bradford Protein Assay (Bio-Rad, Hercules, CA, USA).
Proteins from tissue lysates (30-50 lg) were separated by SDS/PAGE and transferred to nitrocellulose membranes. After blocking, the membranes were incubated with specific primary antibodies overnight at 4°C (anti-Calcineurin 
Quantitative RT-PCR
Total RNA was extracted from frozen and pulverized heart tissue using Trisure reagent (Bioline, Bio-38033, London, UK) and the MagNALyser system (Roche Life Science). RNA was quantified and cDNA synthesized using 2 lg of total RNA and M-MLV reverse transcriptase (Promega, Madison, WI, USA; M170B). The resulting cDNA was analyzed by quantitative real-time PCR (qPCR) in an AB7900 sequence detection PCR system (Applied Biosystem, Foster City, CA, USA) using SYBR Green PCR (Go Taq qPCR Master Mix, Promega, A600A) or TaqMan Universal PCR (Go Taq Probe PCR Master Mix; Promega, A610A). The following TaqMan probes were used: Rcan1.4 (Mm01213406_m1, Mm00627762_m1), Ptgs2 (Mm00478374_m1), Il6 (Mm00446190_m1), and Hprt1 (Mm00446968_m1). The specific probes used for SYBR Green detection were as follows: Cnb1 
Statistical analysis
All data are presented as mean AE SEM (standard error of the mean). Statistical differences were analyzed with GRAPH-PAD PRISM Version 7.03 (GraphPad Inc., La Jolla, CA, USA). Data from different experimental groups were compared by one-way ANOVA followed by Tukey's test, and the adjusted P values for multiple comparisons are indicated. Where indicated, comparisons between two groups were also made by unpaired, two-tailed Student's t-test. Differences were considered statistically significant at P ≤ 0.05. The number of samples and independent experiments in each analysis is indicated in the corresponding figure legend.
